AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington's disease and other neurological disorders; a collaboration with Sernova Corp.; and a research collaboration with The Ohio State University using AgeX's brown adipocyte tissue cell therapy candidate AgeX-BAT1 in mice to determine whether transplantation of AgeX-BAT1 cells may improve diet-induced obesity, metabolic health, and cardiac function. The company was founded in 2017 and is based in Alameda, California.
IPO Year: 2018
Exchange: AMEX
Website: agexinc.com
AgeX Therapeutics, Inc. (("AgeX", NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and nine months ended September 30, 2023. Third Quarter and Recent Highlights $36 Million of Indebtedness Converted into Preferred Stock Signed Agreement and Plan of Merger and Reorganization to Acquire Serina Therapeutics, Inc. Obtained $4.4 million addition to line of credit from Juvenescence Limited Liquidity and Capital Resources Issuance of Preferred Stock to Eliminate $36 Million of Indebtedness During July 2023, AgeX and Juvenescence Limited entered into an Exchange Agreement pursu
AgeX Therapeutics, Inc. (("AgeX", NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported that on July 24, 2023, AgeX issued to Juvenescence Limited 211,600 shares of a newly authorized Series A Preferred Stock and 148,400 shares of a newly authorized Series B Preferred Stock in exchange for the cancellation of a total of $36 Million of indebtedness consisting of the outstanding principal amount of certain loans made by Juvenescence to AgeX and loan origination fees accrued with respect to those loans. The cancellation of indebtedness in exchange for the Preferred Stock was conducted pursuant to an Exchange Agreement between AgeX and Juvenescenc
AgeX Therapeutics, Inc. (("AgeX", NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported that on July 21, 2023, AgeX and Juvenescence Limited entered into an Exchange Agreement pursuant to which AgeX agreed to issue to Juvenescence 211,600 shares of a newly authorized Series A Preferred Stock and 148,400 shares of a newly authorized Series B Preferred Stock in exchange for the cancellation of a total of $36 Million of indebtedness consisting of the outstanding principal amount of certain loans made by Juvenescence to AgeX and loan origination fees accrued with respect to those loans. The exchange of the indebtedness for shares of Series A Pre
8-K - Serina Therapeutics, Inc. (0001708599) (Filer)
10-Q - Serina Therapeutics, Inc. (0001708599) (Filer)
S-1 - Serina Therapeutics, Inc. (0001708599) (Filer)
8-K - Serina Therapeutics, Inc. (0001708599) (Filer)
8-K - Serina Therapeutics, Inc. (0001708599) (Filer)
8-K - AgeX Therapeutics, Inc. (0001708599) (Filer)
8-K - AgeX Therapeutics, Inc. (0001708599) (Filer)
10-K - AgeX Therapeutics, Inc. (0001708599) (Filer)
8-K - AgeX Therapeutics, Inc. (0001708599) (Filer)
425 - AgeX Therapeutics, Inc. (0001708599) (Subject)
ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- AgeX Therapeutics, Inc. (("AgeX", NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2023 and recent highlights. Recent Highlights ●Stockholders approved transactions for merger with Serina Therapeutics, Inc. ●Obtained $4.4 million addition to line of credit from Juvenescence Limited ●Preferred Stock converted into Common Stock ●Completed reverse stock split at a ratio of 1 for 35.17 Liquidity and Capital Resources Issuance of Preferred Stock to Eliminate $36 Million of Indebtedness and
Provides access to Serina POZ polymer technology for potential use in lipid nanoparticle (LNP) formulations HUNTSVILLE, AL, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (Serina), a privately held, clinical stage biotechnology company focused on developing its proprietary POZ Platform TM drug delivery technology, including POZ lipid nanoparticle (LNP) delivery systems for RNA-based therapeutics, today announced Serina has entered into a License Agreement under which Pfizer Inc. will license, on a non-exclusive basis, Serina's POZ polymer technology. "We are excited about the license to Pfizer for its use of the POZ polymer technology in initial research and development acti
AgeX Therapeutics, Inc. (("AgeX", NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and nine months ended September 30, 2023. Third Quarter and Recent Highlights $36 Million of Indebtedness Converted into Preferred Stock Signed Agreement and Plan of Merger and Reorganization to Acquire Serina Therapeutics, Inc. Obtained $4.4 million addition to line of credit from Juvenescence Limited Liquidity and Capital Resources Issuance of Preferred Stock to Eliminate $36 Million of Indebtedness During July 2023, AgeX and Juvenescence Limited entered into an Exchange Agreement pursu
NEW YORK, Sept. 02, 2023 (GLOBE NEWSWIRE) -- Abcam Plc (NASDAQ:ABCM) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of ABCM to Danaher Corporation for $24.00 per share in cash for each share of ABCM common stock owned. If you are an ABCM investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Thorne HealthTech, Inc. (NASDAQ:THRN) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of TRHN to L Catter
Merger to result in NYSE American-listed company focused on developing therapeutics based on Serina's proprietary POZ Platform™ delivery technology Lead program of the combined company will be SER-252 (POZ-apomorphine) for the treatment of advanced Parkinson's Disease Focus on expanding POZ Platform™ partnering collaborations across immunology, cancer Rx, and gene therapy fields Serina Therapeutics, Inc. ("Serina"), a privately-held, clinical-stage biotechnology company developing a pipeline of therapies for the treatment of Parkinson's Disease and other neurological diseases, entered into a merger agreement with AgeX Therapeutics, Inc. (NYSE:AGE) ("AgeX") on August 29, 2023, unde
AgeX Therapeutics, Inc. (("AgeX", NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and six months ended June 30, 2023. Balance Sheet Information Cash, cash equivalents, and restricted cash totaled $0.3 million as of June 30, 2023. Debt Exchanged for Preferred Stock and Line of Credit As of June 30, 2023, AgeX owed Juvenescence Limited ("Juvenescence") $33 million in principal and origination fees on account of loans extended to AgeX. However, during July 2023 AgeX and Juvenescence entered into an Exchange Agreement pursuant to which AgeX issued shares of Series A Preferred Stock
AgeX Therapeutics, Inc. (("AgeX", NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported that on July 24, 2023, AgeX issued to Juvenescence Limited 211,600 shares of a newly authorized Series A Preferred Stock and 148,400 shares of a newly authorized Series B Preferred Stock in exchange for the cancellation of a total of $36 Million of indebtedness consisting of the outstanding principal amount of certain loans made by Juvenescence to AgeX and loan origination fees accrued with respect to those loans. The cancellation of indebtedness in exchange for the Preferred Stock was conducted pursuant to an Exchange Agreement between AgeX and Juvenescenc
AgeX Therapeutics, Inc. (("AgeX", NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported that on July 21, 2023, AgeX and Juvenescence Limited entered into an Exchange Agreement pursuant to which AgeX agreed to issue to Juvenescence 211,600 shares of a newly authorized Series A Preferred Stock and 148,400 shares of a newly authorized Series B Preferred Stock in exchange for the cancellation of a total of $36 Million of indebtedness consisting of the outstanding principal amount of certain loans made by Juvenescence to AgeX and loan origination fees accrued with respect to those loans. The exchange of the indebtedness for shares of Series A Pre
AgeX Therapeutics, Inc. (("AgeX", NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on May 17, 2023 it received a notice from the staff of the NYSE American (the "Exchange") indicating that they intend to commence proceedings to delist AgeX common stock from the Exchange based upon AgeX's non-compliance with the stockholders' equity requirements set forth in Sections 1003(a)(i), (ii) and (iii) of the Exchange's Company Guide by the end of a compliance plan period that expired on May 17, 2023. Specifically, AgeX does not meet the continued listing standards because it has stockholders equity of less than (A) $2,000,000 and has i
AgeX Therapeutics, Inc. (("AgeX", NYSE:AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for quarter ended March 31, 2023. Balance Sheet Information Cash, cash equivalents, and restricted cash totaled $0.3 million as of March 31, 2023. As of March 31, 2023, AgeX owed Juvenescence Limited $33.6 million in principal and origination fees on account of loans extended to AgeX. Increase in Secured Note Line of Credit On May 9, 2023, AgeX and Juvenescence entered into a second amendment to an Amended and Restated Secured Convertible Promissory Note (the "Secured Note") to increase the amount of the line of c
SC 13D - Serina Therapeutics, Inc. (0001708599) (Subject)
SC 13D/A - AgeX Therapeutics, Inc. (0001708599) (Subject)
SC 13D/A - AgeX Therapeutics, Inc. (0001708599) (Subject)
SC 13D/A - AgeX Therapeutics, Inc. (0001708599) (Subject)
SC 13D/A - AgeX Therapeutics, Inc. (0001708599) (Subject)
SC 13D/A - AgeX Therapeutics, Inc. (0001708599) (Subject)
SC 13D/A - AgeX Therapeutics, Inc. (0001708599) (Subject)
SC 13D/A - AgeX Therapeutics, Inc. (0001708599) (Subject)
SC 13D/A - AgeX Therapeutics, Inc. (0001708599) (Subject)
SC 13D/A - AgeX Therapeutics, Inc. (0001708599) (Subject)
4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
3 - Serina Therapeutics, Inc. (0001708599) (Issuer)
4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
3 - Serina Therapeutics, Inc. (0001708599) (Issuer)
3 - Serina Therapeutics, Inc. (0001708599) (Issuer)
3 - Serina Therapeutics, Inc. (0001708599) (Issuer)